Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
adalimumab (Humira®)
Reference No. 2571
Publication date:
10/12/2015
Appraisal information
adalimumab (Humira®) 40 mg/0.8 ml solution for injection
Company:
AbbVie Ltd
BNF category:
Skin
NMG meeting date:
07/10/2015
AWMSG meeting date:
11/11/2015
Submission Type:
Limited Submission
Status:
Recommended with restrictions
Advice No:
3615
Ministerial ratification:
09/12/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification
AWMSG advice
Adalimumab (Humira®) is recommended as an option for restricted use within NHS Wales for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to, or are inappropriate candidates for, topical therapy and phototherapies. Prescribing should be restricted to clinical situations as specified within the National Institute for Health and Care Excellence (NICE) guidance for adults.
Final Appraisal Recommendation (FAR)
Download
adalimumab (Humira) 2571 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
adalimumab (Humira) 2571 ASAR
Clinical Expert (CE) Summary
Download
adalimumab (Humira) 2571 CE Summary
